Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Zhong-Yin Zhang
Purdue University, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tyligand Bioscience, Ltd.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Tyligand Bioscience, Ltd (Tyligand) is a non-publicly traded, early stage drug discovery company, registered in Hong Kong and operating in Shanghai, China. Tyligand is focusing on drug discovery projects that target Protein Tyrosine Phosphatases (PTPs) for cancer and immunology indications, e.g., the discovery of inhibitors against SHP2 and PRL, two subtypes of PTPs. Prof. Zhang is a co-founder of the company and serves as a Chair of its Scientific Advisory Board and as a consultant for the company. This NIH funded project focuses on therapeutic targeting of the oncogenic SHP2 protein tyrosine phosphatase which is implicated in a wide range of leukemia and solid tumors. The overall goal of this research project is to optimize the existing hits into preclinical leads to evaluate the therapeutic potential of targeting SHP2 for anti-cancer treatment. Therefore this project is related to/relevant for the business scope and activities of Tyligand.
Development of SHP2 inhibitors for targeted anti-cancer therapy
This proposal focuses on therapeutic targeting of the oncogenic SHP2 protein tyrosine phosphatase, which is implicated in a wide range of leukemia and solid tumors. We have identified a novel SHP2 inhibitor with promising anti-cancer activity. The overall goal of this research is to optimize the existing hit into preclinical leads to evaluate the therapeutic potential of targeting SHP2 for anti-cancer treatment.
Filed on March 14, 2019.
Tell us what you know about Zhong-Yin Zhang's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.